Article Sidebar

PDF
Date Published: 20/04/2023
Abstract Views: 241
Views PDF: 205
DOI: https://doi.org/10.51298/vmj.v525i1B.5039
Issue
Vol. 525 No. 1B (2023)
Section
Các bài báo
How to Cite
Lê, T. C. ., Lê , T. T. H., Hoàng , H. ., & Nguyễn , T. L. . (2023). THE CURENT OF RIFAMPICIN - RESISTANT TUBERCULOSIS IN THAI NGUYEN AND SOME FACTORS RELATED IN THE PERIOD 2014 - 2022. Vietnam Medical Journal, 525(1B). https://doi.org/10.51298/vmj.v525i1B.5039

THE CURENT OF RIFAMPICIN - RESISTANT TUBERCULOSIS IN THAI NGUYEN AND SOME FACTORS RELATED IN THE PERIOD 2014 - 2022

Tiến Công Lê1, Thị Thanh Hoa Lê 1,, Hà Hoàng 1, Thị Lệ Nguyễn 1
1 Thai Nguyen University Of Medicine And Pharmacy

Main Article Content

Abstract

Objectives: To describe the results of detecting the Rifampicin-resistant tuberculosis in Thai Nguyen in the period 2014 - 2022 and identify some factors related to Rifampicin-resistant tuberculosis in Thai Nguyen. Subjects and Methods: Descriptive study, cross-sectional design. The total sample size was 8044 tuberculosis patients. Results: In the period 2014 - 2022, the rate of Rifampicin-resistant tuberculosis detection was 1.35/100,000 population. The detection rate of Rifampicin-resistant tuberculosis in tuberculosis accounted for 1.91%, of which, 0.82% among new tuberculosis cases and 8.99% among old tuberculosis cases. There is a relationship between sex, age, clinical tuberculosis form and HIV with Rifampicin-resistant tuberculosis status. Conclusion: The detection rate of tuberculosis and Rifampicin-resistant tuberculosis tends to decrease gradually from 2014 to 2022. The factors associated with Rifampicin-resistant tuberculosis are gender, age, clinical tuberculosis type and HIV (p < 0.05).

Article Details

Keywords

Tuberculosis, drug resistance, rifampicin-resistant tuberculosis, detection, Thai Nguyen

References

1. Chương trình chống lao quốc gia, "Báo cáo kết quả hoạt động chương trình chống lao năm 2020 và phương hướng hoạt động năm 2021", Bộ y tế, 2021, Hà Nội.
2. Arega B., Menbere F., Getachew Y., Prevalence of rifampicin resistant Mycobacterium tuberculosis among presumptive tuberculosis patients in selected governmental hospitals in Addis Ababa, Ethiopia, BMC Infect Dis, 2019, 19(1): 307.
3. Bulabula A.N.H., Nelson J.A., Musafiri E.M., et al., Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study, Clin Infect Dis, 2019, 69 (8): 1278 - 1287.
4. Iem V., Dean A., Zignol M., et al., Low prevalence of MDR-TB in Lao PDR: results from the first national anti-tuberculosis drug resistance survey, Trop Med Int Health, 2019, 24(4): 421 - 431. 
5. Lecai J., Mijiti P., Chuangyue H., et al., Predictors and Trends of MDR/RR-TB in Shenzhen China: A Retrospective 2012-2020 Period Analysis, Infect Drug Resist, 2021;14: 4481 - 4491.
6. Suárez-García I., Rodríguez-Blanco A., Vidal-Pérez J.L., et al., Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain, Eur J Clin Microbiol Infect Dis, 2009, 28(4): 325 - 330.
7. Tadesse, Fikadu, "Risk factors for multi-drug resistant tuberculosis in Addis Ababa, Ethiopia." Universal Journal of Public Health 3.2 (2015): 65 - 70. 
8. World Health Organization, Global tuberculosis report 2022, World Health Organization, 2022, Geneva, Switzerland.